Systemic therapy in metastatic renal cell carcinoma

Area of Science:

• Oncology
• Pharmacology
• Nephrology

Background:

• Metastatic renal cell carcinoma (mRCC) treatment has evolved with targeted therapies.
• Vascular endothelial growth factor (VEGF) inhibitors, tyrosine kinase inhibitors (TKIs), and mTOR inhibitors have replaced older cytokine immunotherapies.
• These agents have demonstrated improved progression-free survival in mRCC patients.

Purpose of the Study:

• To review current phase 3 data for approved mRCC treatments.
• To analyze first-, second-, and third-line treatment options and their sequencing.
• To provide expert recommendations based on available evidence and guidelines.

Main Methods:

• Expert panel convened to review phase 3 clinical trial data.
• Incorporated European Association of Urology (EAU) guideline data.
• Collaborative review of approved agents for mRCC.

Main Results:

• Sunitinib and pazopanib are first-line options for favorable/intermediate-risk clear cell RCC (ccRCC).
• Temsirolimus shows benefit in non-clear cell RCC (non-ccRCC) over interferon-alfa.
• Second-line options include TKIs or mTOR inhibitors; third-line options include everolimus and sorafenib. Nivolumab shows promise as a first checkpoint inhibitor in mRCC.

Conclusions:

• Evidence for first- and second-line mRCC therapy is robust, but third-line data is limited.
• Potential sequences include TKI-mTOR-TKI or TKI-TKI-mTOR.
• Emerging checkpoint inhibitors may establish new standards of care following TKI therapy.